Research Article

Association between Plasma Fibrinogen Levels and Mortality in Acute-on-Chronic Hepatitis B Liver Failure

Table 1

Clinical characteristics of enrolled participants.

VariablesControl (171)CHB (173)AoCLF (169) value

Female/male37/13435/13832/1370.825
Age (year)46.43 ± 8.8044.47 ± 9.8246.08 ± 12.900.190
HBsAg positive0173169
HBeAg positive09278
HBV DNA positive0173169
TBIL (μmol/L)12 (6–49)23 (5–430)209 (10–947)*#<0.001
ALT (U/L)17 (7–48)65 (9–1838)65 (10–3686)#<0.001
ALB (g/L)46.5 (40–55.1)37.8 (24.4–52.4)32.4 (20.4–46.2)*#<0.001
Cr (μmol/L)75 (38–100)66 (29–154)65 (23–760)0.004
PT (S)10.8 (9.4–12.7)13.0 (10.1–24.1)22.2 (11.1–120)*#<0.001
Fibrinogen (g/L)2.58 ± 0.491.88 ± 0.561.39 ± 0.58#*<0.001
INR0.94 (0.82–1.10)1.14 (0.88–2.05)1.92 (0.97–10.4)*#<0.001
D-dimer (μg/L FEU)150 (2–510)337 (30–5550)1892 (150–43858)*#<0.001
MELD score6.06 (0.17–20.29)18.88 (3.98–57.17)<0.001
Decompensation (yes/no)0/17388/81*
Mortality (yes/no)0/17360/109*

CHB, chronic hepatitis B; AoCLF, acute-on-chronic hepatitis B liver failure; HBsAg, hepatitis B surface antigen; HBeAg, hepatitis B e antigen; HBV, hepatitis B virus; TBIL, total bilirubin; ALT, alanine aminotransferase; ALB, albumin; Cr, creatinine; PT, prothrombin time; INR, international normalized ratio; FEU, fibrinogen equivalent units; MELD score, the model for end-stage liver disease score.
value: comparison among these three groups. versus the control group. *P < 0.05 versus the CHB group.